As scientists learn more about COVID-19, it has become clear that the virus especially impacts those with existing medical conditions, such as kidney disease.
Explore This Treatment Program
About the Program
The divisions of Nephrology, Cardiology and Endocrinology, and the Corrigan Minehan Heart Center and the Vascular Center, jointly offer a Resistant Hypertension Program which specializes in the evaluation, diagnosis and management of patients with resistant or difficult to treat hypertension. The American Heart Association defines Resistant Hypertension as blood pressure that remains above goal despite the use of three antihypertensive agents in full dose, one of which is a diuretic. Patients with Resistant Hypertension are at high risk for cardiovascular and other complications. The Mass General Resistant Hypertension Program provides a multidisciplinary approach to care, including pharmacologic and non-pharmacologic approaches to blood pressure control as well as interventional options. Services offered include:
- Treatment of Resistant Hypertension
- 24-hour Ambulatory Blood Pressure Monitoring
- Diagnosis and Management of Secondary Hypertension
- Evaluation of Difficult to Treat Hypertension in the context of Cardiovascular Disease
- Evaluation and Management of Secondary Hypertension related to Endocrine Diseases
- Diagnosis and Management of Renal Vascular Hypertension
- Seamless care with referring physicians
- Aug | 18 | 2020
A medida que los científicos van conociendo más sobre el COVID-19, se ha hecho evidente que el virus impacta especialmente a aquellos con condiciones médicas existentes, como la enfermedad renal.
- Mar | 9 | 2020
Partial restoration of kidney function by transplant was significantly associated with improved cardiovascular functional reserve without major change in ventricular structural features.
- Mar | 6 | 2020
With the addition of high-dose cyclophosphamide to graft-versus-host disease prophylaxis, simultaneous stem cell/kidney transplantation is feasible for selected patients who have partially HLA-matched donors.
- May | 16 | 2019
Basic and clinical investigations have identified a role for kidney-derived glycerol-3-phosphate in stimulating circulating fibroblast growth factor 23 after acute kidney injury.
- Nov | 21 | 2018
As an elected ECOR representative, Sylvie Breton, PhD, has advocated for new programs and initiatives to support researchers at Massachusetts General Hospital.